Core Viewpoint - Tianmu Biotech has accused Dapu Biotech of patent infringement regarding the "0MNldrop" microfluidic device, and the Ningbo Intermediate People's Court has accepted the case. Dapu Biotech denies the allegations, asserting that their research and development are legal and compliant, with no infringement occurring [1][2]. Summary by Sections Patent Infringement Allegations - Tianmu Biotech claims that Dapu Biotech's "0MNldrop" microfluidic device infringes on their utility model patent and has filed a lawsuit in the Ningbo Intermediate People's Court, which accepted the case on September 4, 2025 [2][4]. Dapu Biotech's Response - Dapu Biotech refutes the infringement claims, stating that the allegations lack factual support and are merely unilateral assertions. They emphasize that until a final judgment is made by the court, any claims of infringement should not be considered established facts [2][6]. Legal Proceedings and Patent Validity - Dapu Biotech has already filed for a patent invalidation request with the National Intellectual Property Administration prior to Tianmu Biotech's infringement claims. They argue that the patent in question has only undergone formal examination and has not been substantively reviewed, thus violating the disclosure requirements of the Patent Law [5][6]. Commitment to Innovation - Dapu Biotech maintains a focus on independent innovation, having accumulated over 40 related patents. They assert that their products are fundamentally different from the patents claimed by Tianmu Biotech, and they are committed to legal compliance and innovation in the microfluidic technology sector [7][8]. Market Competition and Legal Rights - Dapu Biotech opposes the misuse of litigation to disrupt market competition and emphasizes the importance of fair competition. They plan to actively defend their rights through legal channels and will not tolerate malicious actions that harm their reputation [8][10].